IMARC Group

The study entitled “Biosimilar/Follow-on Biologics Market Report & Forecast: A Focus on the US (2011-2020)” provides a comprehensive insight into the US biosimilar market

IMARC Group has recently released one of the most comprehensive market studies on the Indian Immunodiagnostics market

Implementation of a smart card project requires a significant investment in setting up and upgradation of the current infrastructure. The cost of implementing a smart card based system is very high compared to the cost of smart cards

Driven by factors such as increasing popularity in preliminary testing, portability and ease of use; the market for Immunodiagnostics is expected to grow robustly in the coming years.

A new report from IMARC Group finds that the Indian market for both diagnostic and therapeutic antibodies is expected to grow exponentially in the coming years.

Hybrid vehicles largely depend upon four rare earth elements – Praseodymium, Neodymium, Terbium, and Dysprosium. Out of these four elements, the later three are expected to face a critical supply crunch in the near future.

The performance of HGH biosimilars cannot be taken as an analogue to project the uptake of other biosimilar classes as penetration rates of biosimilars in different biological classes are expected to be different from one another

Smart cards are expected to change the lives of millions of people living in remote villages who have no access to any kind of financial services.

Excluding Mabthera, Roche’s other brands will face biosimilar competition only after 2019. As a result, the company will suffer most of its brand erosion post-2020.

A New Report from IMARC Group expects the growth of the biosimilar market to expand the demand of cold chain logistic services in the coming years.